Background: Automated closed-loop control (CLC), known as the "artificial pancreas" is emerging as a treatment option for Type 1 Diabetes (T1D), generally superior to sensor-augmented insulin pump (SAP) treatment. It is postulated that evening-night (E-N) CLC may account for most of the benefits of 24-7 CLC; however, a direct comparison has not been done. Methods: In this trial (NCT02679287), adults with T1D were randomised 1:1 to two groups, which followed different sequences of four 8-week sessions, resulting in two crossover designs comparing SAP vs E-N CLC and E-N CLC vs 24-7 CLC, respectively. Eligibility: T1D for at least 1 year, using an insulin pumpfor at least six months, ages 18 years or older. Primary hypothesis: E-N CLC compared to SAP will decrease percent time <70mg/dL (3.9mmol/L) measured by continuous glucose monitoring (CGM) without deterioration in HbA1c. Secondary Hypotheses: 24-7 CLC compared to SAP will increase CGM-measured time in target range (TIR, 70-180mg/dL; 3.9-10mmol/L) and will reduce glucose variability during the day. Findings: Ninety-three participants were randomised and 80 were included in the analysis, ages 18-69 years; HbA1c levels 5.4-10.6%; 66% female. Compared to SAP, E-N CLC reduced overall time <70mg/dL from 4.0% to 2.2% () resulting in an absolute difference of 1.8% (95%CI: 1.2-2.4%), p<0.0001. This was accompanied by overall reduction in HbA1c from 7.4% at baseline to 7.1% at the end of study, resulting in an absolute difference of 0.3% (95% CI: 0.1-0.4%), p<0.0001. There were 5 severe hypoglycaemia adverse events attributed to user-directed boluses without malfunction of the investigational device, and no diabetic ketoacidosis events. Interpretation: In type 1 diabetes, evening-night closed-loop control was superior to sensor-augmented pump therapy, achieving most of the glycaemic benefits of 24-7 closed-loop.
RCT Entities:
Background: Automated closed-loop control (CLC), known as the "artificial pancreas" is emerging as a treatment option for Type 1 Diabetes (T1D), generally superior to sensor-augmented insulin pump (SAP) treatment. It is postulated that evening-night (E-N) CLC may account for most of the benefits of 24-7 CLC; however, a direct comparison has not been done. Methods: In this trial (NCT02679287), adults with T1D were randomised 1:1 to two groups, which followed different sequences of four 8-week sessions, resulting in two crossover designs comparing SAP vs E-N CLC and E-N CLC vs 24-7 CLC, respectively. Eligibility: T1D for at least 1 year, using an insulin pump for at least six months, ages 18 years or older. Primary hypothesis: E-N CLC compared to SAP will decrease percent time <70mg/dL (3.9mmol/L) measured by continuous glucose monitoring (CGM) without deterioration in HbA1c. Secondary Hypotheses: 24-7 CLC compared to SAP will increase CGM-measured time in target range (TIR, 70-180mg/dL; 3.9-10mmol/L) and will reduce glucose variability during the day. Findings: Ninety-three participants were randomised and 80 were included in the analysis, ages 18-69 years; HbA1c levels 5.4-10.6%; 66% female. Compared to SAP, E-N CLC reduced overall time <70mg/dL from 4.0% to 2.2% () resulting in an absolute difference of 1.8% (95%CI: 1.2-2.4%), p<0.0001. This was accompanied by overall reduction in HbA1c from 7.4% at baseline to 7.1% at the end of study, resulting in an absolute difference of 0.3% (95% CI: 0.1-0.4%), p<0.0001. There were 5 severe hypoglycaemia adverse events attributed to user-directed boluses without malfunction of the investigational device, and no diabetic ketoacidosis events. Interpretation: In type 1 diabetes, evening-night closed-loop control was superior to sensor-augmented pump therapy, achieving most of the glycaemic benefits of 24-7 closed-loop.
Authors: Sue A Brown; Boris P Kovatchev; Dan Raghinaru; John W Lum; Bruce A Buckingham; Yogish C Kudva; Lori M Laffel; Carol J Levy; Jordan E Pinsker; R Paul Wadwa; Eyal Dassau; Francis J Doyle; Stacey M Anderson; Mei Mei Church; Vikash Dadlani; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; Craig Kollman; Roy W Beck Journal: N Engl J Med Date: 2019-10-16 Impact factor: 91.245
Authors: Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg Journal: Diabetes Technol Ther Date: 2019-01-18 Impact factor: 6.118
Authors: Stacey M Anderson; Bruce A Buckingham; Marc D Breton; Jessica L Robic; Charlotte L Barnett; Christian A Wakeman; Mary C Oliveri; Sue A Brown; Trang T Ly; Paula K Clinton; Liana J Hsu; Ryan S Kingman; Lisa M Norlander; Sarah E Loebner; Suzette Reuschel-DiVirglio; Boris P Kovatchev Journal: Diabetes Technol Ther Date: 2019-05-16 Impact factor: 6.118
Authors: Claudio Cobelli; Eric Renard; Boris P Kovatchev; Patrick Keith-Hynes; Najib Ben Brahim; Jérôme Place; Simone Del Favero; Marc Breton; Anne Farret; Daniela Bruttomesso; Eyal Dassau; Howard Zisser; Francis J Doyle; Stephen D Patek; Angelo Avogaro Journal: Diabetes Care Date: 2012-09 Impact factor: 19.112
Authors: Marc D Breton; Daniel R Cherñavvsky; Gregory P Forlenza; Mark D DeBoer; Jessica Robic; R Paul Wadwa; Laurel H Messer; Boris P Kovatchev; David M Maahs Journal: Diabetes Care Date: 2017-08-30 Impact factor: 19.112
Authors: Sue A Brown; Roy W Beck; Dan Raghinaru; Bruce A Buckingham; Lori M Laffel; R Paul Wadwa; Yogish C Kudva; Carol J Levy; Jordan E Pinsker; Eyal Dassau; Francis J Doyle; Louise Ambler-Osborn; Stacey M Anderson; Mei Mei Church; Laya Ekhlaspour; Gregory P Forlenza; Camilla Levister; Vinaya Simha; Marc D Breton; Craig Kollman; John W Lum; Boris P Kovatchev Journal: Diabetes Care Date: 2020-05-29 Impact factor: 19.112
Authors: Alessandro Bisio; Linda Gonder-Frederick; Ryan McFadden; Daniel Cherñavvsky; Mary Voelmle; Michael Pajewski; Pearl Yu; Heather Bonner; Sue A Brown Journal: J Diabetes Sci Technol Date: 2021-01-15
Authors: Julia Fuchs; Janet M Allen; Charlotte K Boughton; Malgorzata E Wilinska; Ajay Thankamony; Carine de Beaufort; Fiona Campbell; James Yong; Elke Froehlich-Reiterer; Julia K Mader; Sabine E Hofer; Thomas M Kapellen; Birgit Rami-Merhar; Martin Tauschmann; Korey Hood; Barbara Kimbell; Julia Lawton; Stephane Roze; Judy Sibayan; Nathan Cohen; Roman Hovorka Journal: BMJ Open Date: 2021-02-12 Impact factor: 2.692
Authors: Korey K Hood; Lori M Laffel; Thomas Danne; Revital Nimri; Stuart A Weinzimer; Judy Sibayan; Ryan J Bailey; Desmond Schatz; Natasa Bratina; Rachel Bello; Alina Punel; Peter Calhoun; Roy W Beck; Richard M Bergenstal; Moshe Phillip Journal: Diabetes Technol Ther Date: 2021-10-26 Impact factor: 6.118